Table 1.

Details of the Studies Inclued in the Meta-Analysis

Study	Country	Study Design	Total Number of Patients	Median Age	Median Follow-up Time (Month)	Treatment Arms	HR (OS)	P value (OS)	HR (DFS)	P value (DFS)	Study Qulatiy Score	Conclusion	REF
Carey L,2012	USA	Prospective Phase 2	102 71	52(28-83)	26	Cetuximab Cetuximab+Carboplatin	0.381	0.354			4	NS	13
Fan Y,2012	China	Prospective Phase 2	53 27	48(32-67)	24	Dosetaksel+Cisplatin Dosetaksel+Capesitabine	0.41	0.027	0.029	<0,001	3	S	11
Khalaf D,2013	Canada	Retrospective	58	48.9	NR	Various platin based regime			0.97	NR	5	NS	17
Garza CV, 2013	Canada	Retrospective	153 58	53.2	NR	Various platin based regime	0.57	0.002			5	S	14
Hong R, 2014	China	Retrospective	79 34	46	67	Various platin based regime	0.425	0.001			5	S	15
Hu CX, 2015	China	Prospective Phase 3	236 118	47(42-57)	16.3	Gemcitabine +Cisplatin Gemcitabine + Pacitaxel	0.902	0.611	0.692	0.009	4	NS	16
Zhang J, 2015	China	Retrospective	364 218	49(25-76)	15.9	Various platin based regime	0.63	0.002	0.59	0.046	6	S	4